FDA/CDC

FDA approves pembrolizumab for cervical cancer


 

The Food and Drug Administration has approved pembrolizumab (Keytruda) for a new indication: treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express programmed cell death ligand 1, as determined by an FDA approved test.

“This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials,” the FDA said in updated labeling.

FDA icon
Merck’s checkpoint inhibitor, already approved for skin, lung, and gastric cancers, as well as other cancers, won approval for it’s new indication based on 77 patients with tumor programmed cell death ligand 1 combined positive scores of at least 1; almost all had squamous cell cervical carcinoma, but a few had adenocarcinoma or mixed histology, according to labeling.

Two patients (2.6%) had a complete response, and nine (11.7%) had a partial response. Of these 11 patients, 10 had response durations of 6 months or longer. Patients were treated with 200 mg every 3 weeks until unacceptable toxicity or documented disease progression. Over a third had serious adverse reactions, most frequently anemia, fistula, hemorrhage, and infection.

“Keytruda is now the first anti-PD-1 [anti–programmed cell death 1] therapy approved for the treatment of advanced cervical cancer, providing an important new second-line option for certain patients with this disease,” Roy Baynes, MD, a Merck executive, said in a company press release.

Recommended Reading

MDedge Daily News: Do HPV vaccines really cut cancer risk?
MDedge Hematology and Oncology
Intravenous antiemetic combination is well tolerated
MDedge Hematology and Oncology
Is adjuvant chemo warranted in stage I ovarian clear cell carcinoma?
MDedge Hematology and Oncology
Sarcoma dominance in uterine carcinosarcomas linked to decreased survival
MDedge Hematology and Oncology
Female cancer researchers receive less funding than male counterparts
MDedge Hematology and Oncology
Endometrial cancer survivors may need long-term cardiovascular monitoring
MDedge Hematology and Oncology
Tumor analysis: Test all MSI-high patients for Lynch Syndrome
MDedge Hematology and Oncology
Pembrolizumab monotherapy shows activity in advanced recurrent ovarian cancer
MDedge Hematology and Oncology
Trachelectomy rate for early-stage cervical cancer rises to 17% in younger women
MDedge Hematology and Oncology
A new way to classify endometrial cancer
MDedge Hematology and Oncology